Doug Stewart

1.4k total citations
25 papers, 1.0k citations indexed

About

Doug Stewart is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Doug Stewart has authored 25 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Doug Stewart's work include Immunotherapy and Immune Responses (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Immune Cell Function and Interaction (4 papers). Doug Stewart is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Immune Cell Function and Interaction (4 papers). Doug Stewart collaborates with scholars based in Canada, United States and Australia. Doug Stewart's co-authors include Dorcas Fulton, Gregory Cairncross, Edward J. Dropcho, Jan C. Buckner, Clifford Schold, David Macdonald, Terrence L. Cascino, Samuel K. Ludwin, Anthony S. McLean and Peter Forsyth and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Doug Stewart

24 papers receiving 1.0k citations

Peers

Countries citing papers authored by Doug Stewart

Since Specialization

Citations

This map shows the geographic impact of Doug Stewart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doug Stewart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doug Stewart more than expected).

Fields of papers citing papers by Doug Stewart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doug Stewart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doug Stewart. The network helps show where Doug Stewart may publish in the future.

Co-authorship network of co-authors of Doug Stewart

This figure shows the co-authorship network connecting the top 25 collaborators of Doug Stewart. A scholar is included among the top collaborators of Doug Stewart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doug Stewart. Doug Stewart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY 2017 ·Hematological Oncology ·Magdalena Klánová, Laurie H. Sehn, (unknown), Federica Cavallo, Jie Jin, Maurizio Martelli, Doug Stewart, Umberto Vitolo, Francesco Zaja, Q. Zhang, (unknown), Mikkel Z. Oestergaard, Guenter Fingerle-Rowson, Tina Nielsen, Marek Trněný	1
2	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board 2014 ·Clinical Lymphoma Myeloma & Leukemia ·John Kuruvilla, Sarit Assouline, David Hodgson, David MacDonald, Doug Stewart, Anna Christofides, Marina Komolova, (unknown)	15
3	Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma 2014 ·Cancer ·(unknown), (unknown), Greg Dueck, Neil Chua, Daygen L. Finch, James B. Johnston, Richard van der Jagt, Doug Stewart, Darrell White, Andrew R. Belch, Tony Reiman	76
4	Reovirus modulates autophagy during oncolysis of multiple myeloma 2013 ·Autophagy ·Chandini M. Thirukkumaran, Zhong Qiao Shi, Joanne Luider, Karen Kopciuk, He Gao, Nizar J. Bahlis, Paola Neri, Mark Pho, Doug Stewart, Adnan Mansoor, Don Morris	43
5	High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts 2010 ·Bone Marrow Transplantation ·Mette Hoegh-Petersen, Dawn Goodyear, Michelle Geddes, (unknown), Alejandra Ugarte-Torres, (unknown), John T. Walker, K Fonseca, Andrew Daly, Peter Duggan, Doug Stewart, Jeffrey A. Russell, Jan Storek	32
6	Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma 2010 ·Cancer ·Greg Dueck, Neil Chua, (unknown), Daygen L. Finch, Doug Stewart, Darrell White, Richard van der Jagt, James B. Johnston, Andrew R. Belch, Tony Reiman	76
7	Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients 2008 ·Leukemia Research ·Aylin Sar, Marco Perizzolo, Doug Stewart, Adnan Mansoor, Lisa Difrancesco, Douglas J. Demetrick	19
8	Priming with Dendritic Cells Can Generate Strong Cytotoxic T Cell Responses to Chronic Myelogenous Leukemia Cells In Vitro 2004 ·Stem Cells and Development ·Rachel Syme, (unknown), Peter Duggan, (unknown), Doug Stewart, Stefan Glück	2
9	A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131 2004 ·Annals of Oncology ·Karen A. Gelmon, Doug Stewart, (unknown), Stephen Chia, C. Cripps, S. Huan, (unknown), (unknown), Dennis G. Fry, Jennifer A. Shabbits, William R. Walsh, L. McIntosh, Lesley Seymour	18
10	Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals 2004 ·Clinical Cancer Research ·Wenqing Yang, Xueqing Lun, Cheryl A. Palmer, M. Elizabeth Wilcox, Huong Muzik, Zhong Qiao Shi, Richard H. Dyck, Matt Coffey, Brad Thompson, Mark G. Hamilton, Sandra Nishikawa, Penny Brasher, Kevin Fonseca, David H. George, N. B. Rewcastle, Randal N. Johnston, Doug Stewart, Patrick W.K. Lee, Donna L. Senger, Peter Forsyth	62
11	Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT) 2003 ·Bone Marrow Transplantation ·Rachel Syme, Doug Stewart, (unknown), Joanne Luider, (unknown), John S. Klassen, Donald G. Morris, CB Brown, Jeffrey A. Russell, Stefan Glück	10
12	Prophylactic Anticonvulsants in Patients with Brain Tumour 2003 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Peter Forsyth, Susan Weaver, Dorcas Fulton, Penelope M. A. Brasher, Garnette R. Sutherland, Doug Stewart, Neil A. Hagen, Penny J. Barnes, J. G. Cairncross, Lisa M. DeAngelis	117
13	Storage of blood for in vitro generation of dendritic cells 2002 ·Cytotherapy ·Rachel Syme, (unknown), Peter Duggan, (unknown), (unknown), John Wolff, Doug Stewart, Stefan Glück	7
14	Generation of Dendritic Cells Ex Vivo: Differences in Steady State Versus Mobilized Blood from Patients with Breast Cancer, with Lymphoma, and from Normal Donors 2001 ·Journal of Hematotherapy & Stem Cell Research ·Rachel Syme, Peter Duggan, Doug Stewart, Stefan Glück	9
15	Pre‐transplant cardiac testing for kidney–pancreas transplant candidates and association with cardiac outcomes 2001 ·Clinical Transplantation ·(unknown), Doug Stewart, Stephanie Cooper, Connie L. Davis	22
16	A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 131) 2001 ·European Journal of Cancer ·Karen A. Gelmon, Doug Stewart, (unknown), Dennis G. Fry, (unknown), L. McIntosh, Lesley Seymour	2
17	Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: A 10-year experience 2000 ·Biology of Blood and Marrow Transplantation ·JA Russell, A Chaudhry, Karen Booth, Christopher Brown, Richard C. Woodman, (unknown), Doug Stewart, Joseph D. Ruether, Bernard A. Ruether, Ashley Jones, Max J. Coppes, Thomas J. Bowen, Richard A. Anderson, (unknown), (unknown), (unknown), (unknown)	50
18	Factors Influencing Yields of Progenitor Cells for Allogeneic Transplantation: Optimization of G-CSF Dose, Day of Collection, and Duration of Leukapheresis 1997 ·Journal of Hematotherapy ·Joanne Luider, Christopher Brown, (unknown), Diana Quinlan, (unknown), Dean Ruether, Doug Stewart, John S. Klassen, Jeffrey A. Russell	26
19	Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. 1994 ·Journal of Clinical Oncology ·Gregory Cairncross, David Macdonald, Samuel K. Ludwin, (unknown), Terrence L. Cascino, Jan C. Buckner, Dorcas Fulton, Edward J. Dropcho, Doug Stewart, Clifford Schold	335
20	Sulthiame in Treatment of Epilepsy 1964 ·BMJ ·(unknown), Doug Stewart	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact